Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors

Yuechao Zhao, Mary J. Laws, Valeria Sanabria Guillen, Yvonne Ziegler, Jian Min, Abhishek Sharma, Sung Hoon Kim, David Chu, Ben Ho Park, Steffi Oesterreich, Chengjian Mao, David J Shapiro, Kendall W. Nettles, John A. Katzenellenbogen, Benita S Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

Many estrogen receptor α (ERα)–positive breast cancers develop resistance to endocrine therapy via mutation of ERs whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestrogens (AE) against these mutant ERs, we describe here our development and characterization of three chemically novel AEs that effectively suppress proliferation of breast cancer cells and tumors. Our AEs are effective against wild-type and Y537S and D538G ERs, the two most commonly occurring constitutively active ERs. The three new AEs suppressed proliferation and estrogen target gene expression in WT and mutant ER-containing cells and were more effective in D538G than in Y537S cells and tumors. Compared with WT ER, mutants exhibited approximately 10- to 20-fold lower binding affinity for AE and a reduced ability to be blocked in coactivator interaction, likely contributing to their relative resistance to inhibition by AE. Comparisons between mutant ER–containing MCF7 and T47D cells revealed that AE responses were compound, cell-type, and ERα-mutant dependent. These new ligands have favorable pharmacokinetic properties and effectively suppressed growth of WT and mutant ER–expressing tumor xenografts in NOD/SCID-γ mice after oral or subcutaneous administration; D538G tumors were more potently inhibited by AE than Y537S tumors. These studies highlight the differential responsiveness of the mutant ERs to different AEs and make clear the value of having a toolkit of AEs for treatment of endocrine therapy–resistant tumors driven by different constitutively active ERs.

Original languageEnglish (US)
Pages (from-to)5602-5613
Number of pages12
JournalCancer Research
Volume77
Issue number20
DOIs
StatePublished - Oct 15 2017

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Breast Neoplasms
Neoplasms
Inbred NOD Mouse
SCID Mice
MCF-7 Cells
Heterografts
Estrogens
Pharmacokinetics
Ligands
Gene Expression
Mutation
Survival
Therapeutics
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. / Zhao, Yuechao; Laws, Mary J.; Guillen, Valeria Sanabria; Ziegler, Yvonne; Min, Jian; Sharma, Abhishek; Kim, Sung Hoon; Chu, David; Park, Ben Ho; Oesterreich, Steffi; Mao, Chengjian; Shapiro, David J; Nettles, Kendall W.; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.

In: Cancer Research, Vol. 77, No. 20, 15.10.2017, p. 5602-5613.

Research output: Contribution to journalArticle

Zhao, Y, Laws, MJ, Guillen, VS, Ziegler, Y, Min, J, Sharma, A, Kim, SH, Chu, D, Park, BH, Oesterreich, S, Mao, C, Shapiro, DJ, Nettles, KW, Katzenellenbogen, JA & Katzenellenbogen, BS 2017, 'Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors', Cancer Research, vol. 77, no. 20, pp. 5602-5613. https://doi.org/10.1158/0008-5472.CAN-17-1265
Zhao, Yuechao ; Laws, Mary J. ; Guillen, Valeria Sanabria ; Ziegler, Yvonne ; Min, Jian ; Sharma, Abhishek ; Kim, Sung Hoon ; Chu, David ; Park, Ben Ho ; Oesterreich, Steffi ; Mao, Chengjian ; Shapiro, David J ; Nettles, Kendall W. ; Katzenellenbogen, John A. ; Katzenellenbogen, Benita S. / Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. In: Cancer Research. 2017 ; Vol. 77, No. 20. pp. 5602-5613.
@article{ed8ab994bae5430ba2b049f30b9064d0,
title = "Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors",
abstract = "Many estrogen receptor α (ERα)–positive breast cancers develop resistance to endocrine therapy via mutation of ERs whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestrogens (AE) against these mutant ERs, we describe here our development and characterization of three chemically novel AEs that effectively suppress proliferation of breast cancer cells and tumors. Our AEs are effective against wild-type and Y537S and D538G ERs, the two most commonly occurring constitutively active ERs. The three new AEs suppressed proliferation and estrogen target gene expression in WT and mutant ER-containing cells and were more effective in D538G than in Y537S cells and tumors. Compared with WT ER, mutants exhibited approximately 10- to 20-fold lower binding affinity for AE and a reduced ability to be blocked in coactivator interaction, likely contributing to their relative resistance to inhibition by AE. Comparisons between mutant ER–containing MCF7 and T47D cells revealed that AE responses were compound, cell-type, and ERα-mutant dependent. These new ligands have favorable pharmacokinetic properties and effectively suppressed growth of WT and mutant ER–expressing tumor xenografts in NOD/SCID-γ mice after oral or subcutaneous administration; D538G tumors were more potently inhibited by AE than Y537S tumors. These studies highlight the differential responsiveness of the mutant ERs to different AEs and make clear the value of having a toolkit of AEs for treatment of endocrine therapy–resistant tumors driven by different constitutively active ERs.",
author = "Yuechao Zhao and Laws, {Mary J.} and Guillen, {Valeria Sanabria} and Yvonne Ziegler and Jian Min and Abhishek Sharma and Kim, {Sung Hoon} and David Chu and Park, {Ben Ho} and Steffi Oesterreich and Chengjian Mao and Shapiro, {David J} and Nettles, {Kendall W.} and Katzenellenbogen, {John A.} and Katzenellenbogen, {Benita S}",
year = "2017",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-17-1265",
language = "English (US)",
volume = "77",
pages = "5602--5613",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors

AU - Zhao, Yuechao

AU - Laws, Mary J.

AU - Guillen, Valeria Sanabria

AU - Ziegler, Yvonne

AU - Min, Jian

AU - Sharma, Abhishek

AU - Kim, Sung Hoon

AU - Chu, David

AU - Park, Ben Ho

AU - Oesterreich, Steffi

AU - Mao, Chengjian

AU - Shapiro, David J

AU - Nettles, Kendall W.

AU - Katzenellenbogen, John A.

AU - Katzenellenbogen, Benita S

PY - 2017/10/15

Y1 - 2017/10/15

N2 - Many estrogen receptor α (ERα)–positive breast cancers develop resistance to endocrine therapy via mutation of ERs whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestrogens (AE) against these mutant ERs, we describe here our development and characterization of three chemically novel AEs that effectively suppress proliferation of breast cancer cells and tumors. Our AEs are effective against wild-type and Y537S and D538G ERs, the two most commonly occurring constitutively active ERs. The three new AEs suppressed proliferation and estrogen target gene expression in WT and mutant ER-containing cells and were more effective in D538G than in Y537S cells and tumors. Compared with WT ER, mutants exhibited approximately 10- to 20-fold lower binding affinity for AE and a reduced ability to be blocked in coactivator interaction, likely contributing to their relative resistance to inhibition by AE. Comparisons between mutant ER–containing MCF7 and T47D cells revealed that AE responses were compound, cell-type, and ERα-mutant dependent. These new ligands have favorable pharmacokinetic properties and effectively suppressed growth of WT and mutant ER–expressing tumor xenografts in NOD/SCID-γ mice after oral or subcutaneous administration; D538G tumors were more potently inhibited by AE than Y537S tumors. These studies highlight the differential responsiveness of the mutant ERs to different AEs and make clear the value of having a toolkit of AEs for treatment of endocrine therapy–resistant tumors driven by different constitutively active ERs.

AB - Many estrogen receptor α (ERα)–positive breast cancers develop resistance to endocrine therapy via mutation of ERs whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestrogens (AE) against these mutant ERs, we describe here our development and characterization of three chemically novel AEs that effectively suppress proliferation of breast cancer cells and tumors. Our AEs are effective against wild-type and Y537S and D538G ERs, the two most commonly occurring constitutively active ERs. The three new AEs suppressed proliferation and estrogen target gene expression in WT and mutant ER-containing cells and were more effective in D538G than in Y537S cells and tumors. Compared with WT ER, mutants exhibited approximately 10- to 20-fold lower binding affinity for AE and a reduced ability to be blocked in coactivator interaction, likely contributing to their relative resistance to inhibition by AE. Comparisons between mutant ER–containing MCF7 and T47D cells revealed that AE responses were compound, cell-type, and ERα-mutant dependent. These new ligands have favorable pharmacokinetic properties and effectively suppressed growth of WT and mutant ER–expressing tumor xenografts in NOD/SCID-γ mice after oral or subcutaneous administration; D538G tumors were more potently inhibited by AE than Y537S tumors. These studies highlight the differential responsiveness of the mutant ERs to different AEs and make clear the value of having a toolkit of AEs for treatment of endocrine therapy–resistant tumors driven by different constitutively active ERs.

UR - http://www.scopus.com/inward/record.url?scp=85031396653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031396653&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-1265

DO - 10.1158/0008-5472.CAN-17-1265

M3 - Article

VL - 77

SP - 5602

EP - 5613

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -